Angioregressive Pretreatment of Mature Corneal Blood Vessels Before Keratoplasty
- 1 August 2012
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Cornea
- Vol. 31 (8), 887-892
- https://doi.org/10.1097/ico.0b013e31823f8f7a
Abstract
To evaluate the efficacy and safety of combined feeder vessel coagulation and topical antiangiogenic therapy using bevacizumab in the treatment of mature corneal blood vessels. Sixteen eyes of 16 patients with mature corneal neovascularization (NV) due to different underlying corneal diseases underwent fine-needle feeder vessel coagulation by diathermy and were treated postoperatively for up to 4 weeks with topical bevacizumab eye drops (containing 5 mg/mL bevacizumab) 5 times a day. Nine patients received an additional subconjunctival bevacizumab injection at the time of cautery. The mean duration of follow-up was 276 ± 147.3 days (range, 29-464 days). Regression of the feeder vessel was observed in 14 eyes. The vascularized area was reduced significantly (P < 0.05). Combined subconjunctival and eye drop antivascular endothelial growth factor treatment was significantly more effective in reducing the vascularized area compared with antivascular endothelial growth factor eye drop therapy alone (P < 0.05). Five patients (5 eyes) needed a second treatment. Thirteen patients (13 eyes) receiving topical bevacizumab treatment combined with feeder vessel coagulation showed stable visual acuity. Two patients had improved visual acuity. One patient had enlarged area of lipid keratopathy despite successful treatment of corneal NV and thus decreased visual acuity. Overall, there was a nonsignificant improvement of best-corrected visual acuity (P > 0.05). In this pilot study, fine-needle feeder vessel coagulation combined with topical bevacizumab application for treatment of mature corneal NV seemed to be a well-tolerated new treatment option to regress corneal NV. This may not only improve corneal transparency but also "preconditions" such a cornea for future keratoplasty.Keywords
This publication has 17 references indexed in Scilit:
- Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularizationAlbrecht von Graefes Archiv für Ophthalmologie, 2009
- Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmountsExperimental Eye Research, 2008
- Bevacizumab (Avastin) eye drops inhibit corneal neovascularizationAlbrecht von Graefes Archiv für Ophthalmologie, 2007
- Antiangiogene Therapie am vorderen AugenabschnittDer Ophthalmologe, 2007
- Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and visionProceedings of the National Academy of Sciences of the United States of America, 2006
- Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlationBritish Journal of Ophthalmology, 2003
- Corneal neovascularizationCurrent Opinion in Opthalmology, 2001
- Angiogenesis in cancer and other diseasesNature, 2000
- Immunohistochemical Localization of Vascular Endothelial Growth Factor, Transforming Growth Factor α, and Transforming Growth Factor β1 in Human Corneas with NeovascularizationCornea, 2000
- Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal DisordersThe New England Journal of Medicine, 1994